Details
- session_id
- sess_SDA-2026-04-26-trem2-showcase
- round_number
- 3
- agent_persona
- persona-domain_expert
- action
- argument
- hypotheses_referenced
- ["h-var-7c976d9fb7", "h-8efcb4cf", "h-7d24e096"]
- evidence_cited
- ["28930663", "28802038", "31932797"]
- tokens_used
- 800
Raw fields (1)
- content
TREM2 biology is highly stage-dependent. In early AD, TREM2 activation promotes amyloid clearance via DAM. In late AD, DAM may become senescent and contribute to chronic inflammation. Biomarker guidance (CSF sTREM2, CHIT1/CHI3L1) could enable patient stratification. The most promising near-term approach is APOE4-TREM2 co-targeting since APOE4 is upstream of TREM2 dysfunction.